Home Hematology and Oncology High Volume of Enhancing Parenchyma on DCE MRI Tied to Breast Cancer...

High Volume of Enhancing Parenchyma on DCE MRI Tied to Breast Cancer Risk

For women with extremely dense breasts, significantly higher occurrence of breast cancer seen with high volume of enhancing parenchyma

By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 10, 2023 (HealthDay News) — A high volume of enhancing parenchyma on baseline dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) scans is associated with increased occurrence of breast cancer among women with extremely dense breasts, according to a study published online Aug. 8 in Radiology.

Hui Wang, M.D., from the Image Sciences Institute in Utrecht, Netherlands, and colleagues examined quantitative properties of the breast parenchyma on baseline DCE MRI scans and assessed their association with breast cancer occurrence in women with extremely dense breasts. MRI was performed in eight hospitals. After segmentation of fibroglandular tissue, quantitative features of the parenchyma were extracted from baseline MRI. Parenchymal measures with the greatest variance were identified using principal component analysis.

Data were included for 4,553 women with extremely dense breasts; 3 percent were diagnosed with breast cancer. The researchers identified five principal components representing 96 percent of the variance; the component of MRI features relating to volume of enhancing parenchyma explained the greatest independent variance (42 percent). Volume of enhancing parenchyma was associated with breast cancer occurrence in a multivariable analysis (hazard ratio, 1.09). Breast cancer occurrence was significantly higher for women in the highest versus the lowest tertile of volume of enhancing parenchyma (hazard ratio, 2.09).

“To develop personalized screening strategies for breast imaging, more focus is needed on the construction and validation of generalizable risk prediction models based on imaging markers,” the authors write.

One author disclosed ties to Bayer.

Abstract/Full Text

Editorial (subscription or payment may be required)

Copyright © 2023 HealthDay. All rights reserved.